Better potency assays for bispecific antibodies

Prolytix highlights its approach to developing potency assays for bispecific antibodies, focusing on assay designs that align with each molecule’s specific mechanism of action rather than measuring binding affinity alone. Discover how the company offers customized assay strategies that assess both arms of a bispecific antibody using formats such as indirect ELISA, competitive ELISA, bridging ELISA, and multiplexed MSD/ECL methods.

Designed to support the full product lifecycle, the assays can be used for information-only testing, product development, lot release, stability studies, comparability assessments, and regulatory submissions. Theys are developed in alignment with ICH Q2(R2) and current regulatory expectations to facilitate transfer into GMP environments.

Resource details:

Resource type: Scientific poster
Page count: 1
Read time: 2 mins